Press release
Friedreich's Ataxia Pipeline Outlook Report 2025: Tracking the Most Promising Drugs in Clinical Development | DelveInsight
Curious about the latest updates in the Friedreich's Ataxia Pipeline? Click here to explore the therapies and trials making headlines @ Friedreich's Ataxia Pipeline Outlook Report [https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Friedreich's Ataxia Pipeline Report
* On 07 October 2025, Biogen conducted a study is to learn more about the safety of RTA 408 and how it affects physical effort, movement, coordination, and how participants feel in daily life. In this study, researchers are learning more about RTA 408, also known as omaveloxolone, BIIB141, or SKYCLARYS Registered .
* DelveInsight's Friedreich's Ataxia Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Friedreich's Ataxia treatment.
* The leading Friedreich's Ataxia Companies such as PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others.
* Promising Friedreich's Ataxia Therapies such as EPI-743, RT001, Idebenone, Lu AA24493, MIB-626, DT-216P2, CTI-1601, MIN-102 and others.
Want to know which companies are leading innovation in Friedreich's Ataxia? Dive into the full pipeline insights @ Friedreich's Ataxia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Friedreich's Ataxia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Friedreich's Ataxia Pipeline Report also highlights the unmet needs with respect to the Friedreich's Ataxia.
Friedreich's Ataxia Overview
Friedreich's Ataxia (FRDA) is a genetic, progressive, neurodegenerative movement disorder, with a typical age of onset between 10 and 15 years. Initial symptoms may include unsteady posture, frequent falling, and progressive difficulty in walking due to impaired ability to coordinate voluntary movements (ataxia). Affected individuals often develop slurred speech (dysarthria), characteristic foot deformities, and an irregular curvature of the spine (scoliosis).
Friedreich's Ataxia Emerging Drugs Profile
* RT 001: Retrotope
RT001 is a clinical-stage isotopically stabilized, synthetic linoleic acid (LA) discovered and developed with Retrotope's novel platform technology. This platform is designed to combat the oxidative stress and cellular degeneration that arises from lipid peroxidation (LPO). It is currently in phase III stage of development for Friedreich's ataxia and is being developed by Retrotope.
* Leriglitazone: Minoryx Therapeutics
Leriglitazone (MIN-102) is a novel, orally bioavailable and selective PPAR gamma agonist with a potential best-in-class profile indicated for CNS diseases. It is one of the several metabolites of pioglitazone and has a demonstrated sufficient brain penetration and favorable safety profile in humans, allowing PPAR gamma engagement in the CNS above the level that can be safely achieved with pioglitazone and other glitazones. It showed robust preclinical proof-of-concept in animal models of multiple diseases by modulating pathways leading to mitochondrial dysfunction, oxidative stress, neuroinflammation, demyelination and axonal degeneration. It is currently in phase II stage of development and is being developed by Minoryx Therapeutics.
If you're tracking ongoing Friedreich's Ataxia Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Friedreich's Ataxia Treatment Drugs [https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Friedreich's Ataxia Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Friedreich's Ataxia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Friedreich's Ataxia Treatment.
* Friedreich's Ataxia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Friedreich's Ataxia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Friedreich's Ataxia market.
Friedreich's Ataxia Companies
PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others.
Friedreich's Ataxia Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical
* Molecule Type
Friedreich's Ataxia Products have been categorized under various Molecule types such as,
* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type
From emerging drug candidates to competitive intelligence, the Friedreich's Ataxia Pipeline Report covers it all - check it out now @ Friedreich's Ataxia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Friedreich's Ataxia Pipeline Report
* Coverage- Global
* Friedreich's Ataxia Companies- PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others.
* Friedreich's Ataxia Therapies- EPI-743, RT001, Idebenone, Lu AA24493, MIB-626, DT-216P2, CTI-1601, MIN-102 and others.
* Friedreich's Ataxia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Friedreich's Ataxia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Friedreich's Ataxia Treatment landscape in this detailed analysis @ Friedreich's Ataxia Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Friedreich's Ataxia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Friedreich's Ataxia- DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Friedreich's Ataxia Collaboration Deals
* Late Stage Products (Phase III)
* RT 001: Retrotope
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Leriglitazone: Minoryx Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CTI-1601: Larimar Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* LX-2006: LEXEO Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Friedreich's Ataxia Key Companies
* Friedreich's Ataxia Key Products
* Friedreich's Ataxia- Unmet Needs
* Friedreich's Ataxia- Market Drivers and Barriers
* Friedreich's Ataxia- Future Perspectives and Conclusion
* Friedreich's Ataxia Analyst Views
* Friedreich's Ataxia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=friedreichs-ataxia-pipeline-outlook-report-2025-tracking-the-most-promising-drugs-in-clinical-development-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/friedreich-ataxia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Friedreich's Ataxia Pipeline Outlook Report 2025: Tracking the Most Promising Drugs in Clinical Development | DelveInsight here
News-ID: 4243553 • Views: …
More Releases from ABNewswire
From Pandemic Paintings to Luxury Candles: Chere Maison Brings Art and Light to …
Family-operated Chere Maison launches with hand-painted glass candle jars created by self-taught artist Traci Mitchell, who began painting during COVID to spread positivity. The brand combines artisanal craftsmanship with charitable mission to bring joy through functional art.
The transformation of pandemic creativity into entrepreneurial success defines Chere Maison, a new luxury candle brand that emerged from artist Traci Mitchell's COVID-era journey of self-discovery and generous spirit. What began as daily painting…
Hanley Investment Group Arranges $9.2 Million Sale of Starbucks-Anchored Strip C …
SAN JUAN CAPISTRANO, Calif. - Hanley Investment Group Real Estate Advisors, a nationally recognized real estate brokerage and advisory firm specializing in retail property sales, announced today the sale of Rancho Ortega Plaza, a two-story, 23,122-square-foot strip center anchored by Starbucks in San Juan Capistrano, California. The property sold for $9.2 million to a private 1031 exchange buyer in a seven-day escrow.
Hanley Investment Group's Executive Vice President Kevin Fryman and…
Huntington's Disease | Clinical Landscape, Key Companies, Therapeutic Assessment …
DelveInsight's, "Huntington's Disease - Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Huntington's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight's analysis, the Huntington's Disease pipeline features more…
Hyperuricemia: Clinical Overview, Company Landscape, Therapeutic Evaluation, Tre …
DelveInsight's, "Hyperuricemia - Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Hyperuricemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, more than 10 prominent companies are actively developing over…
More Releases for Friedreich
Friedreich Ataxia Market Trends Point to Steady Growth Ahead by 2034, DelveInsig …
The Friedreich's Ataxia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Friedreich's Ataxia pipeline products will significantly revolutionize Friedreich's Ataxia market dynamics.
DelveInsight's "Friedreich's Ataxia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Friedreich's Ataxia, historical and forecasted epidemiology as well as the Friedreich's Ataxia market trends in the United States,…
Friedreich Ataxia Market Insights Highlight Expanding Outlook Till 2034, DelveIn …
The Key Friedreich's Ataxia Companies in the market include - Lexeo Therapeutic, Children's Hospital of Philadelphia, Reata Pharmaceuticals, Retrotope, PTC Therapeutics, Minoryx Therapeutics, and others.
The Friedreich's Ataxia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Friedreich's Ataxia pipeline products will significantly revolutionize Friedreich's Ataxia market dynamics.
DelveInsight's "Friedreich's Ataxia Market Insights, Epidemiology, and Market Forecast-2034 report offers an…
Australian Friedreich Ataxia Therapeutics Market Report with Executive Summary, …
Report Overview
The Australian Friedreich Ataxia (FRDA) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Friedreichs Ataxia (FRDA) is the common inherited ataxia in the Australian. FRDA is a genetic, progressive, neurodegenerative movement disorder, that primarily affects the nervous system and the heart with a typical age of onset between…
United Kingdom Friedreich Ataxia Therapeutics Market Report with Executive Summa …
Report Overview
The UK Friedreich Ataxia (FRDA) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Friedreichs ataxia (FRDA) is the most common inherited ataxia in the UK. FRDA is a genetic, progressive, neurodegenerative movement disorder, that primarily affects the nervous system and the heart with a typical age of onset…
Friedreich Ataxia Drug Market to Witness Growth Acceleration | Adverum Biotechno …
Friedreich Ataxia Drug Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The report answers questions on the current and future technological advancements and development. It delivers an analysis of main manufactures and geographic regions.
The global Friedreich Ataxia Drug market is segmented by company, region (country), type, application, players, stakeholders, and others. The report includes the opportunities and encounters that are faced by…
Friedreich Ataxia Drug Market Emerging Trends || Leading Players are Edison Phar …
The market study on the global Friedreich Ataxia Drug Market will include the entire ecosystem of the industry, covering five major regions namely North America, Europe, Asia Pacific, Latin America and Middle East & Africa, and the major countries falling under those regions. The study will feature estimates in terms of sales revenue and consumption from 2019 to 2026, at the global level and across the major regions mentioned above.…
